CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...